
-
RedHill Biopharma NasdaqCM:RDHL RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Location: 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel | Website: https://www.redhillbio.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
22.7B
Cash
4.617M
Avg Qtr Burn
-2.342M
Short % of Float
0.00%
Insider Ownership
0.00%
Institutional Own.
5.67%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Aemcolo® (rifamycin) Details Bacterial infection | Approved Quarterly sales | |
Movantik® (naloxegol) Details Pain, Constipation, Biliary atresia, Liver disease | Approved Quarterly sales | |
Talicia® (omeprazole magnesium, amoxicillin and rifabutin) Details Bacterial infection | Approved Quarterly sales | |
RHB-104 Details Inflammatory disease, Crohns disease | Phase 3 Update | |
RHB-102 (Bekinda®) Details Digestive tract, Stomach, Intestinal infection | Phase 3 Update | |
RHB-102 (Bekinda®) Details Irritable bowel syndrome, Bowel disorder, Post-traumatic stress disorder, Psychiatric disorder | Phase 3 Initiation | |
Opaganib + Darolutamide Details Castration-resistant prostate cancer | Phase 2 Data readout | |
RHB-107 (upamostat) Details COVID-19 | Phase 2 Data readout | |
Opaganib Details Obesity, Type 2 diabetes | Phase 1 Initiation | |
RHB-106 Details Bowel preparation , Breast cancer | Failed Discontinued | |
Failed Discontinued | ||
RHB-204 Details Bacterial infection | Failed Discontinued |